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Abstract
Background: Osteoarthritis (OA) is a progressive joint disease characterized by gradual degradation of extracellular
matrix (ECM) components in the cartilage and bone. The ECM of cartilage is a highly specified structure that is
mainly composed of type II collagen and provides tensile strength to the tissue via aggrecan and proteoglycans.
However, changes in the ECM composition and structure can lead to loss of collagen type II and network integrity.
Several risk factors have been correlated with OA including age, genetic predisposition, hereditary factors, obesity,
mechanical injuries, and joint trauma. Certain genetic association studies have identified several genes associated
with OA using genome-wide association studies (GWASs).
Results: We identified several novel genetic variants affecting genes that function in several candidate causative
pathways including immune responses, inflammatory and cartilage degradation such as SELP, SPN, and COL6A6.
Conclusions: The approach of whole-exome sequencing can be a promising method to identify genetic mutations
that can influence the OA disease.
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Background
Osteoarthritis (OA) of the knee, which is characterized
by gradual degradation of articular cartilage and sub-
chondral bone, is the most common joint disease occur-
ring worldwide [1, 2]. Approximately 27 million
individuals in the USA alone are estimated to be diag-
nosed with OA which affects about 10% of adults over
age 55 years old [2, 3]. Various risk factors have been as-
sociated with OA including genetic predisposition, obes-
ity, gender, mechanical injuries, physical workload, and
joint trauma. However, age is the most common factor
and affects especially the weight bearing joints, which is
often under mechanical stress [4]. The progression of
OA is a consequence of mechanical, biological, biochem-
ical, and molecular factor interactions. What correlation?
This correlation can disturb the normal series of synthe-
sis and degradation of articular cartilage chondrocytes
and extracellular matrix (ECM) components, and sub-
chondral bone [5, 6]. In normal cartilage ECM there is a
balance between synthesis and degradation that sustain
dynamic equilibrium which can be disrupted if micro-
environment changes in the ECM composition and
structure result in type II collagen loss [7].
Inflammatory stimuli are associated with cartilage
ECM changes in OA and play an essential role in the
pathogenesis of synovium inflammation and cartilage de-
generation through inducing the catabolic activities of
chondrocytes [8, 9]. These Inflammatory factors and cy-
tokines include interleukins family (IL) (IL-1, IL-4, IL-6,
IL-17, IL-18), and tumor necrosis factor- ∝ (TNF- ∝)
[10–14]. For instance, the inflammatory cytokine IL-1β
* Correspondence: mgari@kau.edu.sa
1Sheikh Salem Bin Mahfouz Scientific Chair for Treatment of Osteoarthritis by
Stem Cells, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
2Center of Innovation in Personalized Medicine, King Abdulaziz University,
Jeddah, Kingdom of Saudi Arabia
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The Author(s) BMC Medical Genetics 2016, 17(Suppl 1):68
DOI 10.1186/s12881-016-0330-2
is highly expressed in OA stimulating the expression of
matrix degradation enzymes including MMP-1, MMP-3,
and MMP-13 in chondrocytes and inhibiting ECM syn-
thesis by decreasing the expression SOX9 [15, 16]. This
response ultimately decreases the expression of collagen
type II and aggrecan in articular cartilage that lead to re-
ducing the production of chondrogenic ECM [7].
The genetic predisposition to OA is not fully under-
stood. A number of family studies have investigated the
genetic nature of OA. Familial mutations were identified
in the type II collagen gene (COL2A1) [17]. Mutations
affecting collagen IX gene, and COL9A1 have been
linked to OA of the hip [18]. Recently, various genetic
association studies have identified several genes associ-
ated with OA using genome-wide association studies
(GWASs). These genes include GDF5, DUS4L, Ch7q22,
MCF2L, and GNL3 [19–22]. However, the genetic asso-
ciation between single nucleotide polymorphisms and
OA disease remain controversial.
In this study, a pilot whole-exome sequencing analysis
was performed on osteoarthritis cases in order to identify




Peripheral blood was obtained from five end-stage osteo-
arthritis patients with age range of 46–70 years old. The
collection of these samples were approved by the King
Abdulaziz University Hospital’s ethical committee (No.11–
557). Informed consent was collected from all donors prior
to participation in this study.
Whole- exome sequencing
Genomic DNA was extracted from peripheral blood
samples of five OA cases using QIAamp DNA blood
mini kit according to the manufacture procedure (Qiagen
Inc, USA). Briefly, three micrograms of genomic DNA
were fragmented using the Covaris S2 system. Exome cap-
ture was performed using the Agilent’s SureSelect Whole-
Exome Enrichment kit (v4). Fragment libraries were
prepared from the captured exomes for sequencing on the
SOLiD 5500 platform (Applied Biosystems). Fragments
were sequenced in single reads of 50 bp. Reads were
aligned to the UCSC hg19 reference sequence of the hu-
man genome using the LifeScope analysis pipeline which
was also utilized for variants identification and annotation.
PCR amplification and sanger sequencing
DNA was amplified using custom oligonucleotides
primers listed in Table 1. Polymerase chain reaction re-
actions (PCR) was performed to amplify the selected
primers. The PCR reactions were conducted using Go
Taq Green Master Mix (Promega, USA). The reactions
conditions were performed at one denaturation cycle at
95o C for 15 min followed by 35 cycles of denaturation
at 95o C for 30 s, and annealing at 52o C for 30 s and ex-
tension at 72o C for 30 s. The final step was done at 72o
C for 10 min. To perform Sanger sequencing, purifica-
tion of PCR products using ethanol precipitation were
required prior to the cycle sequencing reaction. Purified
PCR products were labeled with BigDye Terminator kit
v3.1 (ABI Biosystem, USA) for cycle sequencing accord-
ing to the manufacture procedure. After the second
purification for the PCR products, the sequencing ana-
lysis was performed on the automated sequencer from
Applied Biosystems 3500 DNA Analyzer.
Results
Whole-exome sequencing of 5 OA patients revealed several
novel mutations that are predicted to be damaging to pro-
tein function (SIFT). Identified variants were prioritized ac-
cording to their ontology grouping in ECM and/or
inflammation (Table 2). A novel c.381G >T, p.Asn127Lys
mutation in the gene selectin P (SELP) has not been re-
ported in dbSNP, 1000 Genomes project or the ExAC pro-
ject. We have validated this mutation by Sanger sequencing
and confirmed its existence in the heterozygous state in
one patient (Fig. 1). Another novel mutation was identified
in the collagen type VI alpha 6 (COL6A6) gene in another
OA patient. This heterozygous c.2263T >C, p.Ile1137Thr
change was also validated by Sanger sequencing.
Other single nucleotide variants were identified that
had no minor allele frequency reported by dbSNP.
However, they were also found by the ExAC project
albeit at a very low frequency (Fig. 1). These genes
were identified that impact cartilages extracellular
matrix (ECM) organization and cartilage development
Table 1 Primers used for validation of the single nucleotide
variations identified by whole-exome sequencing
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including heparan sulfate proteoglycan2 (HSPG2), sushi
domain containing 5 (SUSD5), integrin subunit alpha 8
(ITGA8), paxillin (PXN), collagen type II alpha 1
(COL2A1), and fidgetin-like 1 (FIGNL1). Moreover, our
results revealed some mutations associated in the inflam-
matory response and immune response such as pyrin do-
main containing 6 (NLRP6) and growth arrest specific 6
(GAS6); ubiquitin specific peptidase 36 (UPS36), sialo-
phorin (SPN), and trinucleotide repeat containing 6B
(TNRC6B) respectively (Table 2).
Discussion
To identify the predisposition genetic factors and the as-
sociation of these candidate genes with the disease, we
conducted a pilot whole-exome sequencing on 5 OA pa-
tients from Saudi Arabia. The result of the exome se-
quence analysis identified several nucleotide variants
affecting candidate genes that could likely contribute in
OA susceptibility and involved in crucial pathways in-
cluding cartilage degradation and development, inflam-
matory, and immune response [5].
The finding of mutations in these genes functionally in-
terrelated to cartilage ECM organization and cartilage sig-
naling pathway may have functional consequences. One of
the identified mutations in this study is the p.Arg4174Cys
mutation found in the HSPG2 gene. This gene plays mul-
tiple roles in the extracellular matrix organization involved
in cartilage development, endochondral bone morpho-
genesis, and chondroitin sulfate metabolic process. Add-
itionally, it is responsible for glycosaminoglycan (GAG)
biosynthetic and catabolic process that maintains the ex-
pression and aggregation of mature chondrogenic markers
[23]. SUSD5 harbors the p.Thr466Met mutation in one OA
patient from our cohort. This gene influences the
Table 2 Single nucleotide variants identified in our whole-exome screen of OA patients and validated by Sanger sequencing
Gene Chromosome position AA change Nucleotide change Protein ID dbSNP ExAC frequency
HSPG2 1,22154535,G,A p.Arg4174Cys c.4391C > T ENSP00000363827 rs199899258 0.00005066
SUSD5 3,33194727,G,A p.Thr466Met c.629C > T ENSP00000308727 rs377664152 0.00009122
ITGA8 10,15628601,G,A p.Ala785Val c.1063C > T ENSP00000367316 rs371802080 0.0000248
PXN 12,120660505,T,C p.Tyr181Cys c.605A > G ENSP00000267257 rs371118243 0.0001199
COL2A1 12,48371204,G,A p.Arg1058Cys c.1487C > T ENSP00000369889 rs148350640 0.00002493
COL6A6 3,130293232,T,C p.Ile1137Thr c.2263T > C ENSP00000351310 rs200274210 0.006855
FIGNL1 7,50513244,A,G p.Met581Thr c.674T > C ENSP00000349356 rs200453649 0.000173
USP36 17,76803235,T,C p.Arg631Gly c.1123A > G ENSP00000441214 rs112843316 0.000082
SPN 16,29676061,C,T p.Arg338Cys c.400C > T ENSP00000353238 rs200681097 0.000485
TNRC6B 22,40661502,G,T p.Gly423Val c.1833G > T ENSP00000401946 rs201057205 0.0003241
SELP 1,169586366,G,T p.Asn127Lys c.381G > T ENSP00000263686 NA NA
NLRP6 11,281256,G,T p.Ala508Ser c.892G > T ENSP00000309767 rs373174851 0.000101
GAS6 13,114535300,G,A p.Pro415Leu c.721C > T ENSP00000349962 NA 0.0000353
Fig. 1 Selected chromatograms showing the Sanger confirmation of identified variants in our samples
The Author(s) BMC Medical Genetics 2016, 17(Suppl 1):68 Page 11 of 23
hyaluronic acid binding, a core component in articular car-
tilage [24]. Another mutation was identified is the
p.Ala785Val mutation in ITGA8, and the p.Tyr181Cys mu-
tation in PXN gene. Both ITGA8 and PXN genes are im-
portant in cellular matrix adhesion, ECM organization, and
transforming growth factor beta receptor regulation [25,
26]. Most importantly, SNPs variants in cartilage related
genes that impacts cartilage development, cartilage conden-
sation, ECM and collagen fibril organization, and collagen
catabolic process has been associated in our OA patients.
That includes the p.Arg1058Cys mutation in COL2A1, and
the p.Ile1137Thr mutation in COL6A6. In addition, the re-
sults of this study showed the p.Met581Thr mutation in
FIGNL1 gene; a gene that influences the regulatory role in
osteoblast proliferation and differentiation [27].
The result of this exome analysis revealed other muta-
tions related to the inflammatory response such as NLRP6
and GAS6; and immune response such as USP36, SPN,
and TNRC6B. The identified mutation in UPS36 gene is
p.Arg631Gly. This gene is a known member of the ubiqui-
tin specific protease family that regulates the immune sig-
naling pathway [28]. The p.Arg338Cys mutation in SPN
was also identified in our patients, and the influence of
this gene can affect cellular defense responses and the
regulation of the tumor necrosis factor (TNF) pathway
[29]. The mutation found in TNRC6B gene is p.Gly423-
Val; this gene not only act in the innate immune response,
but also regulates fibroblast growth factor receptor signal-
ing pathway [30]. Furthermore, the results showed some
other mutations involved in the inflammatory response.
Interestingly, we identified a novel SNV variation in the
SELP, p.Asn127Lys, which has not been reported previ-
ously. The function of SELP is to stimulate leukocytes ad-
hesion in the site of injury, which could explain the
presence of inflammatory markers IL family, and TNF in
OA patients [31]. The p.Ala508Ser mutation in NLRP6
gene, and the p.Pro415Leu mutation in the GAS6 gene
were identified in our screen; both genes regulates the in-
flammatory response [32, 33]. However, GAS6 specifically
regulates tumor necrosis factor-mediated signaling path-
way and macrophage cytokine production [33].
Conclusions
OA is a progressive joint disease characterized by grad-
ual degradation of (ECM) components in the cartilage
and bone. Several risk factors have been associated with
OA such as genetic predisposition and molecular factors.
In this study, a pilot whole-exome sequencing was per-
formed and we identified several genes candidate genes
associated with OA in Saudi Arabia that function in
various causative pathways including immune response,
inflammatory and cartilage degradation. Despite the
small sample size of this group, a hypothesis could be
formulated that states the importance of personalized
genetic screening of OA patients in order to understand
the individual’s genetic makeup potentially responsible
for susceptibility towards OA.
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